Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus LEMTRADA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus LEMTRADA.
FASENRA vs LEMTRADA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody